Skip to Content

Drug Interaction Report

This report displays the potential drug interactions for the following 2 drugs:

  • ibuprofen
  • Aspir-Low (aspirin)

Edit list (add/remove drugs)

Interactions between your drugs

Major

ibuprofen aspirin

Applies to: ibuprofen, Aspir-Low (aspirin)

GENERALLY AVOID: The antiplatelet and cardioprotective effect of low-dose aspirin may be antagonized by coadministration of some nonsteroidal anti-inflammatory drugs (NSAIDs). Ibuprofen has been specifically implicated, and there is evidence that others including indomethacin, naproxen, and tiaprofenic acid may also interact. The mechanism is competitive inhibition of platelet cyclooxygenase by certain NSAIDs, which, unlike aspirin, bind reversibly at the active site of the enzyme and cause a temporary rather than persistent depression of thromboxane formation and thromboxane-dependent platelet function. Unpublished single-dose trials with ibuprofen 400 mg indicate that interference with aspirin's antiplatelet activity, as measured by thromboxane B2 (TXB2) levels and platelet activation studies, occurs when ibuprofen is taken within 8 hours before or 30 minutes after dosing of immediate-release aspirin. One study showed that the antiplatelet effect of enteric-coated low-dose aspirin is attenuated when ibuprofen 400 mg is dosed 2, 7, and 12 hours after aspirin. In contrast, a placebo-controlled study found no clinically significant reduction of TXB2 inhibition when ibuprofen (400 mg three times a day) was coadministered with chewable, immediate-release aspirin (81 mg once a day) for 10 days in healthy volunteers. There are no clinical endpoint studies conducted specifically to evaluate the interaction. A retrospective study of 7107 heart patients discharged from hospitals between 1989 and 1997 with aspirin prescriptions found that those also taking ibuprofen were twice as likely to die during the study period as those taking aspirin alone or with other NSAIDs or acetaminophen. That translates to 12 extra deaths (3 heart-related deaths) a year for every 1000 patients treated. A subgroup analysis from a 5-year randomized, double-blind, placebo-controlled trial of 325 mg aspirin use on alternate days among 22,071 apparently healthy U.S. male physicians with prospective observational data on use of NSAIDs found that regular (>= 60 days/year) but not intermittent (1 to 59 days/year) use of NSAIDs inhibited the clinical benefits of aspirin on first myocardial infarction (MI). Specifically, regular users of NSAIDs in the aspirin group had a greater than 2-fold increased risk of MI, while regular users of NSAIDs in the placebo group had a nonsignificantly reduced risk of MI. There was no association between intermittent use of NSAIDs and subsequent development of MI among aspirin or placebo recipients.

MONITOR CLOSELY: The combined use of aspirin with NSAIDs in general may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Pharmacokinetically, aspirin at anti-inflammatory dosages or higher has been shown to decrease the plasma concentrations of many NSAIDs, including ibuprofen. One study reported a mean 56% reduction in ibuprofen levels during coadministration of aspirin in seven rheumatoid arthritis patients. No change in the elimination half-life of ibuprofen was observed, which suggests an effect on absorption or protein binding of ibuprofen rather than excretion.

MANAGEMENT: Patients receiving low-dose aspirin for cardioprotection should avoid the regular use of ibuprofen and possibly other NSAIDs. Occasional use of ibuprofen is acceptable, as the risk from any attenuation of the antiplatelet effect of low-dose aspirin is likely to be minimal given the long-lasting effect of aspirin on platelets. In patients receiving immediate-release (not enteric-coated) aspirin, single doses of ibuprofen 400 mg may be used but should not be administered within 8 hours before or 30 minutes after the aspirin dose. There are currently no specific recommendations regarding the dosing and timing of single-dose ibuprofen in patients receiving enteric-coated low-dose aspirin. For patients requiring routine NSAID therapy with concomitant low-dose aspirin, diclofenac may be a viable alternative. In the retrospective study implicating ibuprofen, 75 mg twice daily of delayed-release diclofenac did not interfere with the antiplatelet activity of aspirin. Other noninterfering alternatives for pain include acetaminophen, celecoxib, or narcotic analgesics. In any case, caution is advised whenever aspirin is combined with a NSAID due to the potential for additive GI toxicity. Patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.

References

  1. "Concomitant use of ibuprofen and aspirin." J Pain Palliat Care Pharmacother 21 (2007): 73-4
  2. Schafer AI "Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis." J Clin Pharmacol 35 (1995): 209-19
  3. Livio M, Del Maschio A, Cerletti C, de Gaetano G "Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity." Prostaglandins 23 (1982): 787-96
  4. Wilner KD, Rushing M, Walden C, et al. "Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers." J Clin Pharmacol 42 (2002): 1027-30
  5. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N "The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers." Am J Cardiol 101 (2008): 1060-3
  6. FDA. U.S. Food and Drug Administration "Information for healthcare professionals: concomitant use of ibuprofen and aspirin. New information [9/2006] - concomitant use of ibuprofen and aspirin. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand" ([2006 Sept]):
  7. Kurth T, Glynn RJ, Walker AM, et al. "Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs." Circulation 108 (2003): 1191-5
  8. Kimmel SE, Berlin JA, Reilly M, et al. "The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin." J Am Coll Cardiol 43 (2004): 985-90
  9. Bates ER, Mukherjee D, Lau WC "Drug-drug interactions involving antiplatelet agents." Eur Heart J 24 (2003): 1707-9
  10. Capone ML, Sciulli MG, Tacconelli S, et al. "Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects." J Am Coll Cardiol 45 (2005): 1295-301
  11. Cryer B, Berlin RG, Cooper SA, Hsu C, Wason S "Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B(2) concentrations in aspirin-tereated healthy adult volunteers." Clin Ther 27 (2005): 185-91
  12. MacDonald TM, Wei L "Effect of ibuprofen on cardioprotective effect of aspirin." Lancet 361 (2003): 573-4
  13. Grennan DM, Ferry DG, Ashworth ME, Kenny RE, Mackinnnon M "The aspirin-ibuprofen interaction in rheumatoid arthritis." Br J Clin Pharmacol 8 (1979): 497-503
  14. Rao GH, Johnson GG, Reddy KR, White JG "Ibuprofen protects platelet cycloosygenase from irreversible inhibition by aspirin." Arteriosclerosis 3 (1983): 383-8
  15. Catella-Lawson F, Reilly MP, Kapoor SC, et al. "Cyclooxygenase inhibitors and the antiplatelet effects of aspirin." N Engl J Med 345 (2001): 1809-17
View all 15 references

Switch to consumer interaction data

Drug and food interactions

There are no known alcohol/food interactions with your selected drugs. This does not necessarily mean no interactions exist. Always consult your healthcare provider.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Save Interactions List

Sign in to your account to save this drug interaction list.

Save Interactions List

Save to My Med List

Add your drug list to My Med List to view medical information in a simple, easy-to-read, personalized format. Automatically receive FDA alerts, drug interaction warnings, plus data on food, allergy & condition interactions.